Long COVID in Children and Adolescents: A Systematic Review and Meta-analyses.

Sandra Lopez-Leon MD, PhD1,2, Talia Wegman-Ostrosky MD, PhD3, Cipatli Ayuzo del Valle MD4, Carol Perelman, BSc5, Rosalinda Sepulveda MD PhD6, Paulina A Rebolledo, MD, MSc7,8, Angelica Cuapia MD, Dr. Med9, Sonia Villapol, PhD10,11

1Quantitative Safety & Epidemiology, Novartis Pharmaceuticals, New Jersey, USA. ORCID 0000-0001-7504-3441
2Rutgers Center for Pharmacoepidemiology and Treatment Science, Rutgers University, New Jersey, USA.
3Instituto Nacional de Cancerología, Subdirección de Investigación básica, Ciudad de México, México, ORCID 0000-0002-3207-6697
4Departamento de Pediatría, Tecnologico de Monterrey, Mexico. ORCID 0000-0002-8110-3532
5Universidad Nacional Autónoma de México (UNAM), SOMEDICyT, RedMPC, México. ORCID 0000-0002-0111-1154
6Harvard T.H. Chan School of Public Health Boston, Massachusetts, USA. ORCID 0000-0003-1146-9552
7Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.
8Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. ORCID 0000-0002-9808-063X
9Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden. ORCID 0000-0002-9451-1914
10Department of Neurosurgery, Center for Neuregeneration, Houston Methodist Research Institute, Houston, Texas, USA.
11Department of Neuroscience in Neurological Surgery, Weill Cornell Medical College, New York, USA. ORCID 0000-0002-6174-4113

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
ABSTRACT

Objective: To estimate the prevalence of long COVID in children and adolescents and identify the full spectrum of signs and symptoms present after acute SARS-CoV-2 infection.

Methods: Two independent investigators searched PubMed and Embase in order to identify observational studies that met the following criteria: 1) a minimum of 30 patients, 2) ages ranged from 0 to 18 years, 3) published in English, 4) published before February 10th, 2022, and 5) meets the National Institute for Healthcare Excellence (NICE) definition of long COVID, which consists of both ongoing (4 to 12 weeks) and post-COVID-19 (≥12 weeks) symptoms. For COVID symptoms reported in two or more studies, random-effects meta-analyses were performed using the MetaXL software to estimate the pooled prevalence, and Review Manager (RevMan) software 5.4 was utilized to estimate the Odds Ratios (ORs) with a 95% confidence interval (CI). Heterogeneity was assessed using I² statistics. The Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) reporting guideline was followed (registration PROSPERO CRD42021275408).

Results: The literature search yielded 68 articles for long COVID in children and adolescents. After screening, 21 studies met the inclusion criteria and were included in the systematic review and meta-analyses. A total of 80,071 children and adolescents with COVID-19 were included. The prevalence of long COVID was 25.24% (95% CI 18.17-33.02), and the most prevalent clinical manifestations were mood symptoms (16.50%; 95% CI 7.37-28.15), fatigue (9.66%; 95% CI 4.45-16.46), and sleep disorders (8.42%; 95% CI 3.41-15.20). When compared to controls, children infected by SARS-CoV-2 had a higher risk of persistent dyspnea (OR 2.69 95%CI 2.30-3.14), anosmia/ageusia (OR 10.68, 95%CI 2.48, 46.03), and/or fever (OR 2.23, 95%CI 1.22-4.07). The main limitation of these meta-analyses is the probability of bias, which includes lack of standardized definitions, recall, selection, misclassification, nonresponse and/or loss of follow-up, and the high level of heterogeneity.

Conclusion: These meta-analyses provide an overview of the broad symptomatology of long COVID in minors, which may help improve management, rehabilitation programs, and future development of guidelines and therapeutic research for COVID-19.

Keywords: Long COVID, post-acute sequelae of SARS-CoV-2 (PASC), pediatric long hauler, post-COVID children, COVID-19 kids, COVID-19 syndrome
INTRODUCTION

It has been two years since the COVID-19 pandemic was first declared. Consequently, millions of cases and thousands of deaths have been reported worldwide. Still, during this time, treatments have been developed rapidly and effective vaccines have been widely administered to the population, both children and adults, protecting millions from severe disease and death. Until now, the focus was primarily aimed at the acute phase of the disease. However, once the acute phase of COVID-19 is over, many individuals experience months of debilitating COVID-19 symptoms that require additional medical attention and follow-up.

Severe COVID-19 is less common in children than in adults; however, there are two long-term consequences that occur following SARS-CoV-2 infection in children: multisystem inflammatory syndrome (MIS-C) and long COVID. Both of these consequences can even appear in asymptomatic patients. MIS-C is a condition where different body parts become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs. It occurs in less than 0.01% of children with COVID-19 and requires intensive care support in 68% of cases. Long COVID is a heterogeneous multisystemic condition for which there is still no precise definition and includes signs and symptoms that persist, develop, or fluctuate after SARS-CoV-2 infection. Until now, many authors have used the following terms interchangeably when referring to long COVID: long haulers, COVID-long, post-acute sequelae of COVID-19 (PASC), long run, post-COVID, COVID syndrome, and long COVID. In this systematic review, we will refer to long-COVID. In addition, given that MIS-C is a severe disease which complications can persist for years, we will exclude MIS-C studies from this systematic review. In October 2021, the WHO proposed a clinical definition for post-COVID-19 through a Delphi consensus stating it generally occurs three months from the onset of COVID-19, with symptoms lasting at least two months and cannot be explained by an alternative diagnosis. On February 2nd, 2022, the National Institute for Health and Care Excellence in the UK (NICE) published a guideline defining long-COVID as signs and symptoms that continue or develop after acute COVID-19, This includes both ongoing symptomatic COVID-19 (from 4 to 12 weeks) and post-COVID-19 syndrome (12 weeks or more). Other organizations, such as the National Institutes of Health (NIH), also define long COVID as post-acute symptoms after 4 weeks. In the present study, we will use the generic definition from NICE and NIH.

To date, most of the published research on long COVID primarily focuses on adult populations. As a result, there is limited information on the long-term effects of COVID-19 in pediatric populations. One recent meta-analysis studied the persistent symptoms that occur following SARS-CoV-2 infection and examined their prevalence, risk factors, type, and duration. This meta-analysis included studies up to July 2021, encompassing 23,141
children and young people. The most common symptoms were fatigue 47% (95% CI 7-27), dyspnea 43% (95% CI 18-68), and headache 35% (95% CI 19-51). In addition, compared to controls, the prevalence of cognitive difficulties, headache, loss of smell, sore throat, and sore eyes was statistically higher, however due to the lack of data this meta-analysis could only compute the pooled prevalence for 10 symptoms. To date, the potential range of signs and symptoms as well as their frequency of occurrence in children and adolescents remains unclear. There is a need to create awareness among parents, physicians, and researchers on the afflictions following COVID-19 infection, and for the health system to better understand the sequelae in order to provide targeted medical attention and treatment. This systematic review and meta-analyses aim to estimate the prevalence of long COVID in children and adolescents and to identify the full spectrum of signs and symptoms present after COVID-19.

METHODS

Search strategy and selection criteria
This systematic review and meta-analyses examine the prevalence of long COVID signs and symptoms in children under the age of 18 with a diagnosed case of COVID-19 (confirmed via PCR, antigen test, or antibody test). To achieve this, two independent investigators searched PubMed and Embase to identify studies that met the following criteria: 1) a minimum of 30 patients with either ongoing symptomatic COVID-19 (from 4 to 12 weeks) or post-COVID-19 syndrome (12 weeks or more) (i.e., patients who met the NICE definition of long COVID) (NICE 2022), 2) ages ranged from 0 to 18 years, 3) published in English, 4) published before February 10th, 2022, and 5) meets the National Institute for Healthcare Excellence (NICE) definition of long COVID, which consists of both ongoing (4 to 12 weeks) and post-COVID-19 (≥12 weeks) symptoms, 6) excluding cohorts of children composed of exclusively pre-existing chronic diseases, or exclusively of MIS-C in children, and 7) excluding references of editorials, reviews, and commentaries.

The search terms used to identify publications discussing long COVID in children were: (COVID-19 OR COVID OR SARS-CoV-2 OR coronavirus OR "long COVID" OR "post COVID") AND (PASC OR haulers OR lingering OR "post-acute" OR persistent OR convalescent OR convalescence OR sequelae OR post-viral) AND (pediatric OR kids OR young OR infant OR children OR adolescents). Given that MedLine was included in the PubMed search, we excluded articles from MedLine in the Embase search along with those not related to COVID-19. Observational studies, including cohorts and cross-sectional studies, were analyzed only when the cases (numerator) were part of a COVID-19 cohort.
Titles, abstracts, and full texts of articles were independently screened by two authors (TWO and SLL). Each article was thoroughly reviewed by both authors in case there was a difference of opinion on the inclusion of a study based on title or abstract. Disagreement on including a full-text article was discussed among all the authors. The study was registered in PROSPERO [CRD42021275408] (https://www.crd.york.ac.uk/PROSPERO).

Screening and data extraction

Data were extracted by four authors (AC, CA, PR, RS) and Quality-Controlled (QCed) by two authors (TWO, CP). Discrepancies were discussed with a third author. The descriptive variables extracted were country, study design, period of study, collection mode, follow-up time, severity of COVID-19, sample size, COVID-19 diagnosis, age, percentage of males, outcomes, and names used to describe the long-term effects of COVID-19. After duplicates were removed, the search identified 68 papers after screening titles and abstracts. Of these, 21 were included after the exclusion criterion (Figure 1).

Statistical analysis

Random-effects meta-analyses were performed for symptoms reported in two or more studies using MetaXL software to estimate the pooled prevalence, which uses a double arcsine transformation. Prevalence (presented as percentages) with 95% confidence intervals (CIs) was estimated. Numerators represented the number of children with long COVID, and denominators described the total number of children with acute COVID-19 (with and without long-term effects). To compare cases and controls adjusted for confounders, we used the DerSimonian and Laird’s random-effects model. Pooled Odds Ratios (ORs) and 95% CIs were calculated. A p-value < 0.05 was considered statistically significant. Given the heterogeneity expected, a random-effects model was employed using the I² statistics. Values of 25%, 50%, and 75% for I² represented low, medium, and high heterogeneity, respectively. The study's quality control was assessed using the Health States Quality-Controlled data. This index is described and recommended by the MetaXL Guidelines that evaluates the quality of studies assessing prevalence. In addition, the limitations of each study were listed, and they are reported according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines.

RESULTS

General characteristics of studies
The title and abstract of 8,373 publications were screened. Of these, 68 full publications were reviewed, and 47 were excluded because they did not fulfill the inclusion criteria. Thus, a total of 21 studies were selected for analysis (Figure 1). The general study characteristics are shown in Table 1. The majority of the studies assessed pre-specified symptoms included in a questionnaire. The process of study selection is presented in Figure 1. There were 18 studies from Europe (e.g., Denmark, Russia, Italy, Germany, Tukey, Latvia, UK, France, Sweden, and Switzerland), 1 from Iran, 1 from Brazil, and 1 from Australia. The studies by Kikkenborg et al. and Borch et al. included an overlapping population (Denmark), as did the studies by Roge et al. and Smane et al. (Latvia). To ensure that no overlapping data were included, only the study with the largest sample size was included for the estimate of long COVID and for outcomes reported in both studies. Still, several outcomes were only presented in one of the studies, therefore both studies were included in the overall meta-analysis. Four studies included only hospitalized patients, and the rest included all COVID-19 severities (asymptomatic, mild, moderate, and severe). Due to a lack of stratification from all the studies, it was not possible to estimate the prevalence for the different severities. It was only possible to evaluate the prevalence of hospitalized patients. The number of patients included in the studies ranged from 53 to 57,763, and ages ranged from 0 to 18 years. A total of 80,071 children and adolescents with COVID-19 were included in the meta-analyses. We identified more than 40 long-term effects associated with COVID-19 in children and adolescents in the literature reviewed. Different authors have used the terms “Post-acute COVID”, “long COVID,” “Persistent COVID,” “Persistent COVID Symptoms” as synonyms.

**Meta-analyses of the prevalence of long-COVID**

The prevalence of long COVID in children and adolescents, as defined by the presence of one or more symptoms more than 4 weeks following a SARS-CoV-2 infection, was 25.24% (95% CI, 18.17-33.02). For hospitalized patients, the prevalence of long COVID was 29.19% (95% CI, 17.83-41.98). The most common symptoms were mood symptoms (e.g., sadness, tension, anger, depression, and anxiety) (prevalence: 16.50%; 95% CI, 7.37-28.15), fatigue (prevalence: 9.66%; 95% CI, 4.45-16.46), sleep disorders (e.g., insomnia, hypersomnia, and poor sleep quality) (prevalence: 8.42%; 95% CI, 3.41-15.20); headache (prevalence: 7.84%; 95% CI, 4.04-12.70), respiratory symptoms (prevalence: 7.62%; 95% CI, 2.08-15.78), sputum production or nasal congestion (prevalence: 7.53%; 95% CI, 3.78-12.36), cognitive symptoms (e.g., less concentration, learning difficulties, confusion, and memory loss) (prevalence: 6.27%; 95% CI, 4.46-8.35), loss of appetite (prevalence: 6.07%; 95% CI, 3.95-8.59), exercise intolerance (prevalence: 5.73%; 95% CI, 0.00-19.38), and altered smell (e.g.,
hyposmia, anosmia, hyperosmia, parosmia, and phantom smell) (prevalence: 5.60%; 95% CI, 3.13-8.69). All other symptoms had less than 5.00% prevalence (Figure 2 and 3).

**Meta-analyses of ORs (cases vs. controls)**

It was only possible to perform meta-analyses of ORs comparing cases and controls for 13 symptoms (Supplementary Figure 1). Cases were defined as patients that had a confirmed COVID infection, and controls as patients without COVID. When compared to controls, children with long COVID had a higher risk of persistent dyspnea (OR: 2.69; 95% CI, 2.30-3.14), anosmia/ageusia (OR: 10.68; 95% CI, 2.48, 46.03), and/or fever (OR: 2.23; 95% CI, 1.2-4.07). There was significant heterogeneity for 5 out of the 13 meta-analyses.

The controls were chosen in a very different way among studies, which might have introduced significant heterogeneity. The following were the different definitions of controls: 1) children with other infections (e.g., common cold, pharyngotonsillitis, gastrointestinal, urinary tract infections, pneumonia of bacteria or unknown origin) 16; 2) children with no antibodies testing 18 mixed with other children with other infections 16; 3) children with a negative antibody test 19, 4) children with a negative PCR test that were symptomatic 20; and 5) children who did not have a positive test recorded in the database 14.

The adjustments among studies also varied. Several studies adjusted their OR by age, sex, ethnicity, socioeconomic status, and comorbidities 20. However age and sex 14 only adjusted for sex, only age 16 only adjusted for age, and Knoke et al did not adjust, or by OR without adjusting previous conditions 18 (Supplemental Figures 2 and 3).

**Other Findings**

The prevalence of symptoms over the course of long COVID for cases and controls is showed in Supplementary Table 1. Given the heterogeneity in the definition of controls and the low number of subjects, no formal statistical comparison was done for the crude prevalence.

Symptoms that were presented in a single study and, therefore, unable to be incorporated into the meta-analyses included: orthostatic intolerance, cold hands/feet, chapped lips, adenopathy, fainting, twitching of fingers and toes, chills, swollen toes/fingers, and hallucinations. One study reported statistically significant differences between clinical cases and controls for systolic blood pressure, left ventricular ejection fraction, relative myocardial wall thickness, and tricuspid annular plane systolic excursion 21. However, given that these variables were only evaluated in this study, we could not perform a meta-analysis for these outcomes.
Studies included in the meta-analyses evaluated whether certain variables increased the risk of long COVID-19 and found that age, sex, severe acute-COVID-19, obesity, allergic disease, and long-term health conditions were associated with high risk to develop long COVID-19. Further, two of the studies evaluated the duration of symptoms. A study from Denmark reported that symptoms resolved in a minimum of 54–75% of children (varied with age) within 1–5 months. Another, from England, which used the UK ZOE COVID Symptom Study app, reported that 4.4% of children still had symptoms four weeks after COVID-19 onset, which decreased to 1.8% at 8 or more weeks.

**Quality of studies**

Regarding the quality of studies, all had a score of 7 or more. Supplementary Table 1 presents a list of methodological strengths or, conversely, limitations for each study. All studies included laboratory-confirmed COVID-19 infection, PCR or antibody test. Two-thirds of the studies included over 100 children. Six meta-analyses had low heterogeneity (I²<25%) for the following symptoms: vomiting and nausea, nasal congestion, dysphonia, urinary problems, neurological abnormalities, and dysphagia. Three meta-analyses had medium heterogeneity for the following symptoms: abdominal pain, changes in menstruation, and speech disturbances. All other meta-analyses had high heterogeneity (I²>75%). It was not possible to stratify by any variable (e.g., age, sex, country, past comorbidities, or severity) to evaluate where the heterogeneity originated.

**DISCUSSION**

The prevalence of long COVID in children and adolescents, following a COVID-19 infection was 25.24%. The five most prevalent clinical manifestations were mood symptoms (16.50%), fatigue (9.66%), sleep disorders (8.42%), headache (7.84%), and respiratory symptoms (7.62%). It was only possible to perform meta-analyses of ORs comparing cases and controls for 13 symptoms. When compared to controls, persons with COVID-19 had a higher risk of presenting persistent dyspnea, anosmia/ageusia, and/or fever.

The most frequent symptoms reported were related to mood. COVID-19 pandemic has initiated an explosion of future mental illnesses, that is affecting both society as a whole as well as those who recover from COVID-19. Studies have shown that the pandemic has profoundly impacted society by affecting children's development through isolation, poverty, food insecurity, loss of parents and caregivers, loss of time in education, and
increased stress. The presence of these symptoms in the general population, regardless of COVID-19 status, has been coined long-Pandemic Syndrome.

Interestingly, many of the symptoms identified in these meta-analyses, such as mood, fatigue, sleep disorders, orthostatic intolerance, decreased concentration, confusion, memory loss, balance problems, exercise intolerance, hyperhidrosis, blurred vision, body temperature dysregulation, dysfunction on heart, rate variability and palpitations, constipation or diarrhea, and dysphagia, are commonly present in dysautonomia. Dysautonomia is defined as a dysfunction of the sympathetic and/or parasympathetic autonomic nervous system. Postural orthostatic tachycardia syndrome, chronic fatigue syndrome (CFS), and myalgic encephalomyelitis (ME) are subclassifications of this condition. Moreover, the constellation of symptoms because of long COVID can vary from patient to patient, fluctuating in their frequency and severity. Several viruses have been shown to trigger ME/CFS, including the Epstein Barr Virus, Ross River virus, and earlier coronaviruses (e.g., SARS and MERS). However, it remains unclear whether dysautonomia may occur as a direct result of the SARS-CoV-2 infection, interaction with other viruses, or due to immune-mediated processes such as cytokines, which are known mediators of the inflammatory response.

Similar to adults, the following risk factors in the pediatric population were associated with long COVID: older age, female gender, severe COVID-19, overweight/obesity, comorbid allergic diseases, and other long-term co-morbidities. Protective factors leading to milder severity and duration of COVID-19, and possibly also long COVID, in children include fewer comorbidities, strong innate immune responses, reduced expression of ACE2 receptors, and active thymic function, which leads to the increased presence and decreased depletion of T cells which recognize viral proteins. Further protections include a range of environmental or non-inheritable factors such as vaccines, past infections, nutrition, and/or the gut microbiome.

The prevalence of symptoms is highly dependent on how much time has passed after having acute COVID-19. The follow-up time in our meta-analyses varied between 1 to 13 months. Even though most symptoms improve with time, there is evidence in adult studies that suggests some symptoms can persist one year after COVID-19 diagnosis. It is important to understand which symptoms are associated with certain periods of time, so future studies should assess the prevalence of each symptom at different time points (e.g., 6 months, 12 months, 2 years) to determine which symptoms are associated with which time period.
As with other meta-analyses, the strength of this study centers on the large sample size which helps provide identify the signs and symptoms present after acute SARS-CoV-2 infection. Further, there were some limitations to our meta-analyses. The quality of the meta-analyses results depends on the quality of the studies included. Table 3 contains a list of all the methodological aspects that future studies need to consider. We can observe that all studies had a high probability of bias, including lack of standardized definitions recall, selection, misclassification, nonresponse, and/or loss of follow-up. Additionally, the included studies have the limitations inherited in all observational studies, including bias due to residual and unmeasured confounding. Another limitation relates to the high level of heterogeneity. To account for heterogeneity, we used a random-effects model. However, ideally one should stratify the meta-analysis to identify what is causing the heterogeneity. This was not possible because most studies did not include data on different groups. The differences between studies were likely due to differences in study designs, settings, populations, follow-up time, symptom ascertainment methods, inconsistent terminology, little details on stratification on pre-existing comorbidities, and prior receipt of COVID-19 therapeutics and vaccines. Only four studies mentioned what percentage of the population was already vaccinated (Table 3). It has been shown that vaccines reduce the risk of long COVID. A study in Israel compared the prevalence of symptoms of long COVID and found that fully vaccinated participants who had COVID-19 were 54% less likely to report headaches, 64% less likely to report fatigue, and 68% less likely to report muscle pain than were their unvaccinated control group. More studies are needed to analyze the relationship between vaccines in children and long COVID.

Future prospective studies should include a control cohort and stratify and/or adjust their results by age, sex, race, severity of acute COVID-19 infection paired with clinical evaluation, vaccination status, preexisting medical conditions, and, if possible, SARS-CoV-2 variant. If we had analyzed these types of factors separately, we would have been able to discover the variations in the prevalence of long COVID. Retrospective studies using large population-based databases with historical controls and secondary data sources (e.g., claims and medical records) should also be used. The selection of controls will be difficult in the future because not all of the cases are recorded in databases (e.g., home tests), tests can be false negative or positive, or children can be asymptomatic. Proposed control groups for future studies include a negative N protein antibody test without vaccination, a negative antibody test with vaccination, or historical cohorts that include children who have neither been vaccinated nor exposed to the virus.
Protective measures are essential to prevent long COVID in children. We need to understand the long COVID pathophysiology and symptomatology in relation to other post-infectious syndromes to support clinical management systems, establish rehabilitation programs, and design guidelines and therapeutic research. Long COVID represents a significant public health concern, and there are no guidelines to address its diagnosis and management. Our meta-analyses further support the importance of continuously monitoring the impact of long COVID in children and adolescents, and the need to include all variables and appropriated control cohorts in studies to have a better knowledge of the real burden of pediatric long COVID.

**Data availability.**
All data relevant to the study are included in the article or uploaded as supplementary information. In addition, the datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

**Conflict of interest statement.**
SLL is an employee of Novartis Pharmaceutical Company; the statements presented in the paper do not necessarily represent the position of the company. The remaining authors have no competing interests to declare.

**Funding/Support**
This work was supported by funds from Houston Methodist Research Institute, Houston, TX.

**LEGENDS**

**Figure 1. Flow diagram of long COVID studies in children and adolescents.** Preferred Items for Systematic Reviews and Meta-Analyses (PRISMA) flow of the screening process. Out of 8,373 identified studies and after applying the inclusion and exclusion criteria, 21 studies were included in the quantitative synthesis.

**Figure 2. Long-term symptoms of COVID-19 in children and adolescents.** Meta-analyses revealed that the prevalence of long COVID in children and adolescents, as defined by the presence of one or more symptoms following a COVID-19 infection, was 25.24%. This figure was created using Biorender.

**Figure 3.** Estimated incidence rate ratios with 95%-confidence intervals in children and adolescents by long COVID symptoms and domain.
Supplementary Figure 1. Prevalence of symptoms reported over the course of long COVID in children and adolescents who tested positive or negative for SARS-CoV-2 infection.

Supplementary Figure 2. Forest plots for individual long COVID-19 symptoms in children and adolescents (1-17). ORs and 95% CIs for the presence of any category of persistent symptoms for each long COVID study.

Supplementary Figure 3. Forest plots for individual long COVID-19 symptoms in children and adolescents (18-38). ORs and 95% CIs for the presence of any category of persistent symptoms for each long COVID study.
Table 1. General Characteristics of Studies.

| Author       | Country | Study Design | Collection mode                          | Follow up time included in MA | Severity % | N cases (denominator) | N controls | COVID diagnoses | Control definition | Age range | Sex % Male | Term                     |
|--------------|---------|--------------|------------------------------------------|--------------------------------|------------|------------------------|------------|-----------------|---------------------|-----------|------------|-------------------------|
| Asadi Pooya  | Iran    | CSS          | Phone (questionnaire)                    | >3 months                      | Hospitalized | 58                     | NA         | PCR             | NA                  | 6 to 17   | 48%        | Long COVID              |
| Blankenburg  | Germany | CSS          | Schools (survey)                         | >3 months                      | NR         | 188                    | 1365       | IgG             | IgG negative       | 14 to 16   | 45%        | Long-COVID19            |
| Borch        | Denmark | RCS          | Electronic (questionnaire)               | >1 month                        | Asymptomatic | 15,041                 | 15,080     | PCR             | Not a PCR positive in the past | 0 to 17   | NR         | Long COVID              |
| Buonsenso    | Italy   | CSS          | Phone or inpatient (questionnaire)       | >4 months                      | All severities | 129                   | NA         | PCR             | NA                  | >18       | 52%        | Long COVID              |
| Erol         | Turkey  | RCS          | Clinical                                 | 5.6 months average             | All severities | 121                   *95 | “tested positive” | Not having contact with someone with Covid.19 | >18       | 54%        | Long Covid              |
| Fink         | Brasil  | PCS          | Outpatient and inpatient validated instrument and clinic | 4.4 months average | Symptomatic (Outpatient and inpatients) | 53          *52 | PCR or antibody | *Negative PCR or antibody | 8 to 18   | 42%        | Post-COVID-19/long.term PASC/ Long COVID-19 |
| Kikkenborg Berg | Denmark | CSS          | Electronic (survey)                      | 2 months                        | All severities | 6,630                  | 21,640     | Tested positive | Not tested positive | 15 to 18  | 58%        | Long COVID              |
| Knoke        | Germany | CSS          | Outpatient (questionnaire and pulmonary function testing) | 2.6 months average | Asymptomatic | 73                     | 45         | PCR or antibody | No antibodies, 31% other infection | 5 to 18   | 48%        | Long term COVID/persistent symptoms |
| Matteudi     | France  | PCS          | Phone (questionnaire)                    | 10 to 13 months                 | All severities | 137                   | NA         | PCR             | NA                  | 0 to 15   | NR         | Long-term consequences/persisting symptoms/ Long COVID |
| Miller       | UK      | PCS          | Electronic (weekly survey)               | ≥ 1 month                       | NR         | 174                    | NA         | “nasal swab”    | NA                  | ≤17       | 45%        | Persistent symptoms/ long covid |

CC-BY-NC-ND 4.0 International license. It is made available under a CC BY-NC-ND license. The copyright holder for this preprint this version posted March 13, 2022. doi: medRxiv preprint
| Study     | Country   | Data Collection Method | Follow-Up Time | Symptoms/Prognosis | PCR or Seroconversion | Other Infections | Long-Term/SARS-CoV-2 Postviral Syndromes | Persistent Symptoms |
|-----------|-----------|------------------------|----------------|--------------------|----------------------|------------------|------------------------------------------|---------------------|
| Molteni   | UK        | PCS Electronic App     | >2 months      | NR                 | NA                   | PCR IgG          | NA                                       | 50%                 |
| Osmanov   | Russia    | PCS Phone (SARIC COVID-19 Health and Wellbeing Follow-Up Survey for Children) | >5 months | Hospitalized       | 518                  | NA              | PCR                                      | 47%                 |
| Radtke    | Switzerland | PCS Online (questionnaire) | >3 months | Asymptomatic and mild | 109                  | 1246            | Serology Seronegative                    | 46%                 |
| Roge      | Latvia    | PCS and RCS Phone (questionnaire) | 1 to 6 months | All severities | 236                  | 142             | PCR or seroconversion Other infections | 55.50%              |
| Roessler  | Germany   | RCS Health Insurance data | ≥3 months     | All severities      | 57,763               | *288,815         | Laboratory virus detection Non-laboratory virus detection | 51.30%              |
| Rusetsky  | Russia    | PCS Phone              | At 2 months   | Hospitalized       | 79                   | NA              | PCR                                      | Persistent          |
| Say       | Australia | PCS Clinical           | 3 to 6 months | All severities     | 151                  | NA              | PCR                                      | 58%                 |
| Smane     | Latvia    | RCS Clinical           | 1 to 3 months | Hospitalized       | 92                   | NA              | NR                                       | 61%                 |
| Stephenson| UK        | PCS Paper questionnaire | At 3 months   | Non-hospitalized    | 3065                 | 3739            | PCR                                      | 37%                 |
| Sterky    | Sweden    | PCS Phone questionnaire | Median 7.3, range 4.1 to 10.8 months | Hospitalized | 55                   | NA              | PCR                                      | 58%                 |
| Zavala    | UK        | RCS Paper questionnaire | At 1 month    | All severities     | 387                  | 472             | PCR                                      | 51%                 |
Controls: did not present numbers, therefore it could not be used. CSS = cross-sectional study, DM = diabetes mellitus, NA = not applicable, NR = not reported, MA = meta-analysis M = months, PCS = prospective cohort study, RCS = retrospective cohort study

* Part of the population duplicated.
Table 2. Clinical manifestations of Long-COVID in children and adolescents.

| CLINICAL MANIFESTATIONS | Studies | Cases | Sample Size | Prevalence % (95%CI) |
|-------------------------|---------|-------|-------------|----------------------|
| Mood (sad, tense, angry, depression, anxiety) | 5       | 730   | 6047        | 16.5 (7.37-28.15)    |
| Fatigue                 | 16      | 3015  | 21592       | 9.66 (4.45-16.46)    |
| Sleep disorder (insomnia, hyporsomnia, poor sleep quality) | 8       | 153   | 1592        | 8.42 (3.41-15.20)    |
| Headache                | 13      | 1875  | 21108       | 7.84 (4.04-12.70)    |
| Respiratory symptoms    | 9       | 1387  | 19013       | 7.62 (2.08-15.78)    |
| Sputum/nasal congestion | 2       | 11    | 150         | 7.53 (3.78-12.36)    |
| Cognition (less concentration, learning difficulties, confusion, memory loss) | 11      | 1223  | 19803       | 6.27 (4.46-8.35)     |
| Exercise intolerance    | 2       | 8     | 150         | 5.73 (0.00-19.38)    |
| Altered smell (hyposmia, anosmia) | 10      | 2048  | 20818       | 5.60 (3.13-8.69)     |
| Condition                                      | Count | N  | Count | OR   |
|-----------------------------------------------|-------|----|-------|------|
| anosmia, hyperosmia, parosmia, phantom smell | 6     | 467| 18777 | 4.62 |
| Chest pain                                    | 5     | 747| 9379  | 6.07 |
| Rhinorrhea                                    | 5     | 65 | 1032  | 4.15 |
| Dizziness                                     | 6     | 791| 9340  | 4.40 |
| Myalgia/arthralgia                            | 9     | 547| 19564 | 3.76 |
| Cough                                         | 10    | 570| 19688 | 3.80 |
| Hyperhidrosis                                 | 2     | 36 | 738   | 4.66 |
| Ophthalmologic (conjuntivitis, dry eye, problems seeing/blurred vision, photophobia, pain) | 6     | 384| 9411  | 3.00 |
| Otalgia (tinnitus, earache, vertigo)          | 3     | 207| 3773  | 3.41 |
| Altered taste                                 | 5     | 1273| 16005 | 3.65 |
|                          | No. | Avg. | IQR      | Median |
|--------------------------|-----|------|----------|--------|
| Body weight changes      | 3   | 30   | 865      | 3.99 (0.00-14.00) |
| Fever                    | 5   | 167  | 18709    | 1.87 (0.50-3.99) |
| Abdominal pain           | 8   | 277  | 9611     | 2.91 (2.04-3.92) |
| Sore Throat              | 6   | 401  | 10311    | 2.47 (0.25-6.23) |
| Dermatologic (dry skin, itchy skin, rashes, hives) | 6 | 218 | 9322 | 2.61 (1.73-3.67) |
| Variations in heart rate | 2   | 18   | 729      | 2.29 (0.00-7.36) |
| Diarrhea                 | 7   | 218  | 19337    | 1.68 (0.63-3.18) |
| Constipation             | 3   | 20   | 1101     | 2.05 (0.39-4.75) |
| Dysphonia                | 2   | 62   | 3301     | 1.89 (1.45-2.38) |
| Chest tightness          | 5   | 293  | 6319     | 2.45 (0.58-5.35) |
| Musculoskeletal other    | 3   | 383  | 15618    | 1.72 (0.41-3.78) |
| Vomiting/nausea          | 5   | 260  | 16144    | 1.53 (1.09-2.03) |
| Condition                                  | Count | Total | Frequency | Odd Ratio (95% CI) |
|--------------------------------------------|-------|-------|-----------|--------------------|
| Changes in menstruation                    | 3     | 10    | 866       | 1.27 (0.38-2.60)   |
| Hair loss                                  | 3     | 16    | 1209      | 1.17 (0.10-3.10)   |
| Palpitations                               | 4     | 165   | 6178      | 1.27 (0.00-3.83)   |
| Neurological abnormalities (pins and needles, tremor, numbness) | 3     | 8     | 997       | 0.86 (0.37-1.55)   |
| Urinary symptoms                           | 3     | 6     | 1060      | 0.63 (0.23-1.21)   |
| Dysphagia                                  | 3     | 5     | 1207      | 0.46 (0.14-0.93)   |
| Speech Disturbances                        | 3     | 5     | 1197      | 0.44 (0.05-1.10)   |
Table 3. Study methodological strength.

| Study methodological Strength                                                                 | Nº of studies (N=21) | Prevalence (%) |
|------------------------------------------------------------------------------------------------|----------------------|----------------|
| COVID cases lab confirmed (PCR or antibody)                                                   | 21                   | 100            |
| More than 100 COVID patients                                                                  | 14                   | 66.66          |
| Timing of COVID well specified                                                                | 14                   | 66.66          |
| Long COVID defined >3 months                                                                  | 8                    | 38.10          |
| Point in time specific and well defined                                                      | 10                   | 42.11          |
| Control added                                                                                 | 8                    | 31.6%          |
| Control group with negative antibody test                                                     | 2                    | 10.5           |
| Clinical assessment (not self/ parent reported)                                               | 7                    | 36.84          |
| New symptoms on or after COVID                                                                | 6                    | 31.58          |
| Specify if persistent symptom or if it is symptoms months after acute COVID                   | 2                    | 9.52           |
| Exclude vaccinated / no vaccinated in sample                                                   | 4                    | 19.05          |
| Duration (end) of symptoms specified                                                         | 3                    | 14.29          |
| Validated questionnaires or Clinical evaluation for symptoms                                  | 5                    | 23.81          |

**Bias**

| Bias                                              |                      |                |
|---------------------------------------------------|----------------------|----------------|
| Low chance of Recall Bias                         | 7                    | 33.33          |
| Low chance of Selection Bias                      | 4                    | 19.05          |
| Low chance of Misclassification Bias              | 3                    | 14.29          |
| Low chance of Nonresponse bias/ Loss of follow up | 3 | 14.29 |
|-----------------------------|---|---|
| **Stratifications** | | |
| Stratify by severity/ only one severity | 4 | 19.05 |
| Stratified by age/ only one age group studied | 6 | 28.57 |
| Stratified by preexisting medical conditions | 1 | 4.76 |
| Stratified by sex | 2 | 9.52 |
| Stratify by vaccination status | 0 | 0 |
REFERENCES

1. Cucinotta, D. & Vanelli, M. WHO Declares COVID-19 a Pandemic. *Acta Biomed* **91**, 157-160, doi:10.23750/abm.v91i1.9397 (2020).

2. Update to living WHO guideline on drugs for covid-19. *BMJ* **376**, o534, doi:10.1136/bmj.o534 (2022).

3. Chua, P. E. Y. *et al.* Epidemiological and clinical characteristics of non-severe and severe pediatric and adult COVID-19 patients across different geographical regions in the early phase of pandemic: a systematic review and meta-analysis of observational studies. *J Investig Med* **69**, 1287-1296, doi:10.1136/jim-2021-001858 (2021).

4. Kundu, A. *et al.* Clinical aspects and presumed etiology of multisystem inflammatory syndrome in children (MIS-C): A review. *Clin Epidemiol Glob Health* **14**, 100966, doi:10.1016/j.cegh.2022.100966 (2022).

5. Helms, J. *et al.* Neurologic Features in Severe SARS-CoV-2 Infection. *N Engl J Med* **382**, 2268-2270, doi:10.1056/NEJMc2008597 (2020).

6. Soriano, J. B. *et al.* A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis* doi:10.1016/S1473-3099(21)00703-9 (2021).

7. Clements, W., Joseph, T. & Koukounaras, J. UK NICE Guidelines for EVAR: Cost Implications for Post-COVID Australian Public Health. *Cardiovasc Intervent Radiol* **44**, 1286-1288, doi:10.1007/s00270-021-02832-2 (2022).

8. Nalbandian, A. *et al.* Post-acute COVID-19 syndrome. *Nat Med* **27**, 601-615, doi:10.1038/s41591-021-01283-z (2021).

9. Behnood, S. A. *et al.* Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies. *J Infect* **84**, 158-170, doi:10.1016/j.jinf.2021.11.011 (2022).

10. Lopez-Leon, S. *et al.* More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *Sci Rep* **11**, 16144, doi:10.1038/s41598-021-95565-8 (2021).

11. Team, C. C.-R. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. *MMWR Morb Mortal Wkly Rep* **69**, 422-426, doi:10.15585/mmwr.mm6914e4 (2020).

12. Barendregt, J. J., Doi, S. A., Lee, Y. Y., Norman, R. E. & Vos, T. Meta-analysis of prevalence. *J Epidemiol Community Health* **67**, 974-978, doi:10.1136/jech-2013-203104 (2013).

13. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials revisited. *Contemp Clin Trials* **45**, 139-145, doi:10.1016/j.cct.2015.09.002 (2015).

14. Kikkenborg Berg, S. *et al.* Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. *Lancet Child Adolesc Health*, doi:10.1016/S2352-4642(22)00004-9 (2022).

15. Borch, L., Holm, M., Knudsen, M., Ellermann-Eriksen, S. & Hagstroem, S. Long COVID symptoms and duration in SARS-CoV-2 positive children - a nationwide cohort study. *Eur J Pediatr*, doi:10.1007/s00431-021-04345-z (2022).

16. Roge, I. *et al.* Comparison of Persistent Symptoms After COVID-19 and Other Non-SARS-CoV-2 Infections in Children. *Front Pediatr* **9**, 752385, doi:10.3389/fped.2021.752385 (2021).

17. Smane, L., Roge, I., Pucuka, Z. & Pavare, J. Clinical features of pediatric post-acute COVID-19: a descriptive retrospective follow-up study. *Ital J Pediatr* **47**, 177, doi:10.1186/s13052-021-01127-z (2021).

18. Knoke L, S. A., Maier C, Eitner L, Lücke T, Brinkmann F. More complaints than findings - Long-term pulmonary function in children and adolescents after COVID-19. *medRxiv* **06.22.21259273**, doi:https://doi.org/10.1101/2021.06.22.21259273 (2021).

19. Radke, N., Ruanwiboonsuk, P., Tham, C. C. Y., Jonas, J. B. & Lam, D. S. C. Ophthalmology and COVID-19: Long-term Surveillance Needed. *Asia Pac J Ophthalmol (Phila)* **10**, 519-520, doi:10.1097/APO.0000000000000449 (2021).
20 Zavala, M., Ireland, G., Amin-Chowdhury, Z., Ramsay, M. E. & Ladhani, S. N. Acute and persistent symptoms in children with PCR-confirmed SARS-CoV-2 infection compared to test-negative children in England: active, prospective, national surveillance. *Clin Infect Dis*, doi:10.1093/cid/ciab991 (2021).
21 Erol, N., Alpinar, A., Erol, C., Sari, E. & Alkan, K. Intriguing new faces of Covid-19: persisting clinical symptoms and cardiac effects in children. *Cardiol Young*, 1-7, doi:10.1017/S1047951121003693 (2021).
22 Asadi-Pooya, A. A. *et al.* Long COVID in children and adolescents. *World J Pediatr* 17, 495-499, doi:10.1007/s12519-021-00457-6 (2021).
23 Osmanov, I. M. *et al.* Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. *Eur Respir J* 59, doi:10.1183/13993003.01341-2021 (2022).
24 Molteni, E. *et al.* Long COVID in children - Authors’ reply. *Lancet Child Adolesc Health* 6, e3, doi:10.1016/S2352-4642(21)00344-8 (2022).
25 Miller F, N. V., Navaratnam A, Shrotri M, Kovar J, Hayward AC, Fragaszy E, Aldridge RW, Hardelid P. Prevalence of persistent symptoms in children during the COVID-19 pandemic: evidence from a household cohort study in England and Wales. *medRxiv* 05.28.21257602, doi:https://doi.org/10.1101/2021.05.28.21257602 (2021).
26 Solmi, M. *et al.* Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). *J Affect Disord* 299, 367-376, doi:10.1016/j.jad.2021.09.090 (2022).
27 Ravens-Sieberer, U. *et al.* [Mental health and psychological burden of children and adolescents during the first wave of the COVID-19 pandemic-results of the COPSY study]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 64, 1512-1521, doi:10.1007/s00103-021-03291-3 (2021).
28 Blankenburg, J. *et al.* Comparison of mental health outcomes in seropositive and seronegative adolescents during the COVID19 pandemic. *Sci Rep* 12, 2246, doi:10.1038/s41598-022-06166-y (2022).
29 Dotan, A., David, P., Arnheim, D. & Shoenfeld, Y. The autonomic aspects of the post-COVID19 syndrome. *Autoimmun Rev* 21, 103071, doi:10.1016/j.autrev.2022.103071 (2022).
30 Yong, S. J. & Liu, S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. *Rev Med Virol*, e2315, doi:10.1002/rmv.2315 (2021).
31 Sharif, K. *et al.* On chronic fatigue syndrome and nosological categories. *Clin Rheumatol* 37, 1161-1170, doi:10.1007/s10067-018-4009-2 (2018).
32 Siberry, V. G. R. & Rowe, P. C. Pediatric Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Overlaps and Opportunities. *Pediatr Infect Dis J*, doi:10.1097/INF.0000000000003477 (2022).
33 Evans, S. S., Repasky, E. A. & Fisher, D. T. Fever and the thermal regulation of immunity: the immune system feels the heat. *Nat Rev Immunol* 15, 335-349, doi:10.1038/nri3843 (2015).
34 Atzeni, F. *et al.* One year in review 2019: fibromyalgia. *Clin Exp Rheumatol* 37 Suppl 116, 3-10 (2019).
35 Caronna, E. & Pozo-Rosich, P. Headache during COVID-19: Lessons for all, implications for the International Classification of Headache Disorders. *Headache* 61, 385-386, doi:10.1111/head.14059 (2021).
36 Barzien, N. *et al.* Clinical characterization of dysautonomia in long COVID-19 patients. *Sci Rep* 11, 14042, doi:10.1038/s41598-021-93546-5 (2021).
37 Brodin, P. *et al.* Variation in the human immune system is largely driven by non-heritable influences. *Cell* 160, 37-47, doi:10.1016/j.cell.2014.12.020 (2015).
38 Seessle, J. *et al.* Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. *Clin Infect Dis*, doi:10.1093/cid/ciab611 (2021).
39 Fumagalli, C. et al. Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study. *Eur J Intern Med*, doi:10.1016/j.ejim.2021.11.018 (2021).

40 Finckh, A. & Tramer, M. R. Primer: strengths and weaknesses of meta-analysis. *Nat Clin Pract Rheumatol* 4, 146-152, doi:10.1038/ncprheum0732 (2008).

41 Cumpston, M. et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. *Cochrane Database Syst Rev* 10, ED000142, doi:10.1002/14651858.ED000142 (2019).

42 Kuodi, P. G. Y., Zayyad, H, Wertheim, O, Wiegler, KB, Jabal, KA, Nazzal, S, Glikman, D and Edelstein, M. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. *medRxiv* 01.05.22268800, doi:https://doi.org/10.1101/2022.01.05.22268800 (2022).

43 Buonsenso, D. et al. Preliminary evidence on long COVID in children. *Acta Paediatr* 110, 2208-2211, doi:10.1111/apa.15870 (2021).

44 Fink, T. T. et al. Persistent symptoms and decreased health-related quality of life after symptomatic pediatric COVID-19: A prospective study in a Latin American tertiary hospital. *Clinics (Sao Paulo)* 76, e3511, doi:10.6061/clinics/2021/e3511 (2021).

45 Matteudi, T. et al. Clinical characteristics of paediatric COVID-19 patients followed for up to 13 months. *Acta Paediatr* 110, 3331-3333, doi:10.1111/apa.16071 (2021).

46 Rossler, R. et al. A Multinational Cluster Randomised Controlled Trial to Assess the Efficacy of ‘11+ Kids’: A Warm-Up Programme to Prevent Injuries in Children’s Football. *Sports Med* 48, 1493-1504, doi:10.1007/s40279-017-0834-8 (2018).

47 Rusetsky, Y. et al. Smell Status in Children Infected with SARS-CoV-2. *Laryngoscope* 131, E2475-E2480, doi:10.1002/lary.29403 (2021).

48 Say, D. et al. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. *Lancet Child Adolesc Health* 5, e22-e23, doi:10.1016/S2352-4642(21)00124-3 (2021).

49 Stephenson, T. et al. Long COVID and the mental and physical health of children and young people: national matched cohort study protocol (the CLoCk study). *BMJ Open* 11, e052838, doi:10.1136/bmjopen-2021-052838 (2021).

50 Sterky, E. et al. Persistent symptoms in Swedish children after hospitalisation due to COVID-19. *Acta Paediatr* 110, 2578-2580, doi:10.1111/apa.15999 (2021).
Identification of studies via databases and registers

Records identified from PubMed (n = 7,445)

Records screened (n = 8,373)

Out of scope (n = 8,305)

Records identified through Embase (n = 928)

Full text assessed for eligibility (n = 68)

Reports excluded: (n = 47)
Reasons:
- Protocol, review, commentary (n = 11)
- Includes patients older than 18 (n = 4)
- Less than 30 patients/case reports (n = 11)
- Not long- COVID-19 (acute / MISC) (n = 10)
- Non denominator (n = 5)
- Data combined with adults (n = 3)
- Survey to paediatrics (n = 2)
- Abstract (n = 1)

Studies Included (n = 21)
| Symptom                  | Odd Ratio (95% CI) | Mood                      | Odd Ratio (95% CI) |
|-------------------------|--------------------|---------------------------|--------------------|
| Age 15-18 (vs. no positive test) | 0.62 (0.74, 0.51)   |                           |                    |
| Age 0-18 (vs. other infections) | 16.00 (4.69, 55.65) |                           |                    |
| Zarala age 0-18 (vs. PCR neg symptomatic) | 3.94 (1.16, 13.36)  |                           |                    |
| Subtotal (95% CI) | 3.46 (0.91, 13.27)   |                           |                    |
| Heterogeneity: Tau^2 = 2.59; Chi^2 = 27.80, df = 2 (P < 0.0001); I^2 = 93% | Test for overall effect: Z = 1.28 (P = 0.20) |  |
| Fatigue                 |                    |                           |                    |
| Age 15-18 (vs. no positive test) | 1.00 (0.98, 1.15)    |                           |                    |
| Knoke age 5-18 (vs. no antibiotics other infection) | 3.16 (0.70, 14.54)   |                           |                    |
| Age 0-18 (vs. other infections) | 8.70 (2.56, 30.29)   |                           |                    |
| Subtotal (95% CI) | 2.79 (0.96, 8.17)     |                           |                    |
| Heterogeneity: Tau^2 = 1.32; Chi^2 = 12.69, df = 2 (P = 0.002); I^2 = 84% | Test for overall effect: Z = 1.40 (P = 0.19) |  |
| Headache                |                    |                           |                    |
| Age 15-18 (vs. no positive test) | 1.22 (1.10, 1.35)    |                           |                    |
| Knoke age 5-18 (vs. no antibiotics other infection) | 1.44 (0.38, 5.46)    |                           |                    |
| Age 0-18 (vs. other infections) | 10.90 (1.70, 71.67)  |                           |                    |
| Subtotal (95% CI) | 1.95 (0.69, 5.82)     |                           |                    |
| Heterogeneity: Tau^2 = 0.53; Chi^2 = 5.24, df = 2 (P = 0.07); I^2 = 62% | Test for overall effect: Z = 1.25 (P = 0.21) |  |
| Dyspnea                 |                    |                           |                    |
| Age 15-18 (vs. no positive test) | 2.70 (2.31, 3.16)    |                           |                    |
| Knoke age 5-18 (vs. no antibiotics other infection) | 1.63 (0.15, 17.71)   |                           |                    |
| Age 0-18 (vs. other infections) | 2.10 (0.20, 22.20)   |                           |                    |
| Subtotal (95% CI) | 2.69 (2.33, 3.14)     |                           |                    |
| Heterogeneity: Tau^2 = 0.00; Chi^2 = 0.21, df = 2 (P = 0.60); I^2 = 0% | Test for overall effect: Z = 12.49 (P < 0.00001) |  |
| Concentration problems |                    |                           |                    |
| Age 15-18 (vs. no positive test) | 1.04 (0.97, 1.12)    |                           |                    |
| Age 0-18 (vs. other infections) | 13.60 (1.70, 108.61) |                           |                    |
| Subtotal (95% CI) | 3.62 (0.25, 38.19)     |                           |                    |
| Heterogeneity: Tau^2 = 2.74; Chi^2 = 5.86, df = 1 (P = 0.02); I^2 = 63% | Test for overall effect: Z = 0.87 (P = 0.38) |  |
| Anosmia/ Ageusia        |                    |                           |                    |
| Age 0-18 (vs. other infections) | 11.20 (1.40, 89.61)  |                           |                    |
| Zarala age 0-18 (vs. PCR neg symptomatic) | 10.20 (1.21, 78.41)  |                           |                    |
| Subtotal (95% CI) | 1.43 (0.25, 8.63)     |                           |                    |
| Heterogeneity: Tau^2 = 0.00; Chi^2 = 0.00, df = 1 (P = 0.55); I^2 = 0% | Test for overall effect: Z = 3.18 (P < 0.001) |  |
| Loss of appetite        |                    |                           |                    |
| Age 15-18 (vs. no positive test) | 1.15 (1.02, 1.30)    |                           |                    |
| Age 0-18 (vs. other infections) | 2.50 (0.90, 6.95)    |                           |                    |
| Subtotal (95% CI) | 1.09 (0.25, 4.63)     |                           |                    |
| Heterogeneity: Tau^2 = 0.18; Chi^2 = 2.19, df = 1 (P = 0.14); I^2 = 54% | Test for overall effect: Z = 1.02 (P = 0.31) |  |
| Rhinitis                |                    |                           |                    |
| Knoke age 5-18 (vs. no antibiotics other infection) | 0.14 (0.03, 0.66)    |                           |                    |
| Age 0-18 (vs. other infections) | 2.60 (1.30, 5.20)    |                           |                    |
| Subtotal (95% CI) | 1.43 (0.94, 11.44)     |                           |                    |
| Heterogeneity: Tau^2 = 3.90; Chi^2 = 11.49, df = 1 (P = 0.0007); I^2 = 91% | Test for overall effect: Z = 0.29 (P = 0.77) |  |
| Myalgia/ arthralgia     |                    |                           |                    |
| Age 15-18 (vs. no positive test) | 1.09 (0.91, 1.31)    |                           |                    |
| Knoke age 5-18 (vs. no antibiotics other infection) | 1.24 (0.33, 4.46)    |                           |                    |
| Subtotal (95% CI) | 1.09 (0.25, 4.63)     |                           |                    |
| Heterogeneity: Tau^2 = 0.00; Chi^2 = 0.04, df = 1 (P = 0.85); I^2 = 0% | Test for overall effect: Z = 0.97 (P = 0.33) |  |
| Cough                   |                    |                           |                    |
| Age 15-18 (vs. no positive test) | 1.63 (1.43, 1.86)    |                           |                    |
| Knoke age 5-18 (vs. no antibiotics other infection) | 0.24 (0.06, 0.66)    |                           |                    |
| Age 0-18 (vs. other infections) | 1.60 (0.90, 4.01)    |                           |                    |
| Subtotal (95% CI) | 1.20 (0.55, 2.89)     |                           |                    |
| Heterogeneity: Tau^2 = 0.32; Chi^2 = 7.46, df = 2 (P = 0.02); I^2 = 73% | Test for overall effect: Z = 0.40 (P = 0.69) |  |
| Fever                   |                    |                           |                    |
| Age 15-18 (vs. no positive test) | 1.53 (0.74, 3.16)    |                           |                    |
| Knoke age 5-18 (vs. no antibiotics other infection) | 2.66 (0.67, 10.60)   |                           |                    |
| Age 0-18 (vs. other infections) | 4.00 (1.40, 11.43)   |                           |                    |
| Subtotal (95% CI) | 2.23 (1.22, 4.07)     |                           |                    |
| Heterogeneity: Tau^2 = 0.04; Chi^2 = 2.26, df = 2 (P = 0.32); I^2 = 12% | Test for overall effect: Z = 2.81 (P = 0.009) |  |
| Sore throat             |                    |                           |                    |
| Age 15-18 (vs. no positive test) | 1.59 (1.21, 2.06)    |                           |                    |
| Knoke age 5-18 (vs. no antibiotics other infection) | 0.44 (0.12, 1.61)    |                           |                    |
| Age 0-18 (vs. other infections) | 3.90 (0.70, 17.50)   |                           |                    |
| Subtotal (95% CI) | 1.34 (0.54, 3.42)     |                           |                    |
| Heterogeneity: Tau^2 = 0.37; Chi^2 = 4.62, df = 2 (P = 0.10); I^2 = 57% | Test for overall effect: Z = 0.83 (P = 0.53) |  |
| Nausea/ Vomiting        |                    |                           |                    |
| Age 15-18 (vs. no positive test) | 1.09 (0.92, 1.26)    |                           |                    |
| Age 0-18 (vs. other infections) | 6.20 (0.80, 46.66)   |                           |                    |
| Subtotal (95% CI) | 1.73 (0.38, 7.81)     |                           |                    |
| Heterogeneity: Tau^2 = 0.80; Chi^2 = 2.12, df = 1 (P = 0.15); I^2 = 53% | Test for overall effect: Z = 0.71 (P = 0.47) |  |

OR (95% CI)